FC-002

FC-002 is a small molecule inhibitor of the cystine-glutamate transporter xCT (SLC7A11), currently in preclinical development by FeroptoCure for the treatment of solid tumors. By inhibiting xCT, the drug blocks the uptake of cystine, which is a critical precursor for the synthesis of glutathione (GSH). The resulting depletion of GSH leads to an accumulation of lipid peroxides, ultimately inducing a form of regulated cell death known as ferroptosis. This therapeutic approach specifically targets the metabolic vulnerabilities of cancer cells that overexpress xCT to maintain redox homeostasis and survive under high oxidative stress.